読み込み中
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
前日終値
$3.83
+$0.04 · +1.06%
日中の時刻はETです。市場データは遅延する場合があります。
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
日中レンジ
現在 $3.83
52週レンジ
現在 $3.83
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
25
割高
センチメント
74
強気
リスク
44
やや高いリスク
モメンタム
71
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
日中レンジ
現在 $3.83
52週レンジ
現在 $3.83
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 782.6万 USD | 1872万 USD | 3124.9万 USD | 2975.2万 USD | 676.1万 USD |
| 売上原価 | 209.1万 USD | 279.2万 USD | 1808.1万 USD | 1196万 USD | 471.3万 USD |
| 粗利益 | 573.5万 USD | 1592.8万 USD | 1316.8万 USD | 1779.2万 USD | 204.8万 USD |
| 研究開発 | 5264.5万 USD | 3358.6万 USD | 9838.4万 USD | 7781.3万 USD | 4381.3万 USD |
| 販売・一般管理 | 2197.2万 USD | 2220.3万 USD | 3109.8万 USD | 2513.3万 USD | 2361.9万 USD |
| 営業費用 | 8211万 USD | 1.58億 USD | 1.11億 USD | 1.08億 USD | 9177.1万 USD |
| 受取利息 | 763.7万 USD | 795.3万 USD | — | — | — |
| 減価償却費と償却費 | 45.4万 USD | 80.7万 USD | 86.3万 USD | 79.7万 USD | 92.3万 USD |
| 営業利益 | −7637.5万 USD | −1.42億 USD | −9735.7万 USD | −8985.4万 USD | −8972.3万 USD |
| 純利益 | −6492.3万 USD | −1.32億 USD | −8848.1万 USD | −8690.8万 USD | −9086.5万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$10.60
上昇余地（176.76%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2567.23万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM1190.31万0.02%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF887.06万0.01%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO412.24万0.02%180億 USD0.06%$112.66+0.50%
State Street SPDR S&P Pharmaceuticals ETFXPH391.39万0.85%4.62億 USD0.35%$64.65+1.60%
iShares Russell 2000 Growth ETFIWO362.74万0.03%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB330.74万0.03%108.2億 USD0.44%$206.49+3.00%
Fidelity Enhanced Small Cap ETFFESM320.01万0.05%64.1億 USD0.28%$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBFidelity Enhanced Small Cap ETFFESMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
